In most inflammatory bowel diseases, IL-1β acts together with other proinflammatory cytokines such as IL-6 and tumor necrosis factor-α or IL-23 in the inflammatory process, and treatment alone against the proinflammatory effects of IL-1β has little effect. This evidence concerns the gene IL1B and inflammatory bowel disease.